MedTrace Logo

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

NCT00142480 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-04-25

No results posted yet for this study

Summary

The main purpose of this study is to test the safety and effectiveness of oxaliplatin, bevacizumab, and capecitabine given in combination with radiation therapy to see what effects (good or bad) they have on patients with biliary tract and gallbladder cancer.

Conditions

  • Biliary Tract Cancer
  • Gallbladder Adenocarcinoma

Interventions

DRUG

Capecitabine

Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).

DRUG

Oxaliplatin

Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29

DRUG

Bevacizumab

Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.

PROCEDURE

Radiation therapy

Once daily for 5 days (Monday through Friday) for a total of 28 treatments.

Sponsors & Collaborators

Principal Investigators

  • Andrew Zhu, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2007-07-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00142480 on ClinicalTrials.gov